Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Free Cash Flow: 2016-2025

Historic Free Cash Flow for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to -$26.6 million.

  • Rhythm Pharmaceuticals' Free Cash Flow fell 5.58% to -$26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$109.1 million, marking a year-over-year increase of 12.29%. This contributed to the annual value of -$113.9 million for FY2024, which is 16.39% up from last year.
  • Rhythm Pharmaceuticals' Free Cash Flow amounted to -$26.6 million in Q3 2025, which was down 14.19% from -$23.3 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Free Cash Flow peaked at -$18.8 million during Q4 2024, and registered a low of -$53.8 million during Q1 2022.
  • In the last 3 years, Rhythm Pharmaceuticals' Free Cash Flow had a median value of -$29.3 million in 2023 and averaged -$30.9 million.
  • In the last 5 years, Rhythm Pharmaceuticals' Free Cash Flow crashed by 60.27% in 2022 and then spiked by 37.87% in 2023.
  • Over the past 5 years, Rhythm Pharmaceuticals' Free Cash Flow (Quarterly) stood at -$40.5 million in 2021, then climbed by 16.13% to -$34.0 million in 2022, then increased by 13.58% to -$29.4 million in 2023, then spiked by 35.86% to -$18.8 million in 2024, then dropped by 5.58% to -$26.6 million in 2025.
  • Its Free Cash Flow stands at -$26.6 million for Q3 2025, versus -$23.3 million for Q2 2025 and -$40.4 million for Q1 2025.